Association of Emergency Department Buprenorphine Initiation With Subsequent Pharmacotherapy and Outcomes Among Patients With Opioid Use Disorder
Abstract
Objectives: To examine trends in emergency department (ED) buprenorphine initiation and evaluate its association with outcomes in the 180 days following discharge.
Methods: This observational cohort study used 2018-2022 New Jersey Medicaid claims data from patients presenting to EDs for opioid-related causes, excluding visits that resulted in inpatient admission. We used prescription and encounter data to identify patients with opioid use disorder (OUD) or opioid overdose who initiated buprenorphine in the ED and propensity score matching to compare outcomes of initiators and noninitiators. Outcomes measured during 180-day follow-up were the proportion of days covered (PDC) with medication for OUD (MOUD) and the number of drug overdoses, opioid overdoses, and all-cause ED/inpatient visits within 180 days.
Results: Buprenorphine was initiated in 978 of 24,732 (4.0%) opioid-related ED visits, with this proportion increasing from 0.8% in 2018 to 7.1% in 2022. Buprenorphine initiation was associated with greater MOUD PDC (β=0.10, 95% CI: 0.08-0.13) and fewer all-cause ED/inpatient visits (IRR=0.87, 95% CI: 0.77-0.98) during follow-up. We did not find a statistically significant association between ED buprenorphine initiation and postdischarge overdose; however, greater PDC in the 180-day follow-up period was associated with fewer drug overdoses (IRR=0.80, 95% CI: 0.68-0.94), opioid overdoses (IRR=0.78, 95% CI: 0.67-0.91), and all-cause ED/inpatient visits (IRR=0.89, 95% CI:…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.